Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Analysis of cytokine profile and growth factors in platelet-rich plasma obtained by open systems and commercial columns.

Pochini AC, Antonioli E, Bucci DZ, Sardinha LR, Andreoli CV, Ferretti M, Ejnisman B, Goldberg AC, Cohen M.

Einstein (Sao Paulo). 2016 Jul-Sep;14(3):391-397. doi: 10.1590/S1679-45082016AO3548. English, Portuguese.

2.

Effect of Human Adipose Tissue Mesenchymal Stem Cells on the Regeneration of Ovine Articular Cartilage.

Zorzi AR, Amstalden EM, Plepis AM, Martins VC, Ferretti M, Antonioli E, Duarte AS, Luzo AC, Miranda JB.

Int J Mol Sci. 2015 Nov 9;16(11):26813-31. doi: 10.3390/ijms161125989.

3.

Modulation of Hyaluronan Synthesis by the Interaction between Mesenchymal Stem Cells and Osteoarthritic Chondrocytes.

Antonioli E, Piccinato CA, Nader HB, Cohen M, Goldberg AC, Ferretti M.

Stem Cells Int. 2015;2015:640218. doi: 10.1155/2015/640218. Epub 2015 Jul 26.

4.

Analysis of epidemiology, lifestyle, and psychosocial factors in patients with back pain admitted to an orthopedic emergency unit.

Gotfryd AO, Valesin Filho ES, Viola DC, Lenza M, Silva JA, Emi AS, Tomiosso R, Piccinato Cde A, Antonioli E, Ferretti M.

Einstein (Sao Paulo). 2015 Apr-Jun;13(2):243-8. doi: 10.1590/S1679-45082015AO3320. English, Portuguese.

5.

High OCT4 and Low p16(INK4A) Expressions Determine In Vitro Lifespan of Mesenchymal Stem Cells.

Piccinato CA, Sertie AL, Torres N, Ferretti M, Antonioli E.

Stem Cells Int. 2015;2015:369828. doi: 10.1155/2015/369828. Epub 2015 May 21.

6.

Update on biological therapies for knee injuries: osteoarthritis.

Pintan GF, de Oliveira AS Jr, Lenza M, Antonioli E, Ferretti M.

Curr Rev Musculoskelet Med. 2014 Sep;7(3):263-9. doi: 10.1007/s12178-014-9229-8.

7.

Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.

Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, Polverelli N, Ruggeri M, Vannucchi AM, Antonioli E, Lussana F, Tieghi A, Iurlo A, Elli E, Ruella M, Fabris F, Cazzola M, Barbui T.

Am J Hematol. 2014 Mar;89(3):306-9. doi: 10.1002/ajh.23635. Epub 2014 Feb 19.

8.

An evaluation of chondrocyte morphology and gene expression on superhydrophilic vertically-aligned multi-walled carbon nanotube films.

Antonioli E, Lobo AO, Ferretti M, Cohen M, Marciano FR, Corat EJ, Trava-Airoldi VJ.

Mater Sci Eng C Mater Biol Appl. 2013 Mar 1;33(2):641-7. doi: 10.1016/j.msec.2012.10.010. Epub 2012 Nov 2.

PMID:
25427468
9.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

10.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

11.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10.

12.

Risk of second cancers in chronic myeloproliferative neoplasms.

Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, Bosi A, Vannucchi AM.

Blood. 2012 Apr 19;119(16):3861-2; author reply 3862-3. doi: 10.1182/blood-2011-12-401455. No abstract available.

13.

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.

Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, De Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM; AGIMM Investigators.

Am J Hematol. 2012 May;87(5):552-4. doi: 10.1002/ajh.23160. Epub 2012 Apr 4.

14.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.

Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Am J Hematol. 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. Epub 2012 Jan 11.

15.

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Leukemia. 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. Epub 2011 Sep 16.

PMID:
21926959
16.

ID1 inhibits USF2 and blocks TGF-β-induced apoptosis in mesangial cells.

Sato AY, Antonioli E, Tambellini R, Campos AH.

Am J Physiol Renal Physiol. 2011 Dec;301(6):F1260-9. doi: 10.1152/ajprenal.00128.2011. Epub 2011 Sep 14.

17.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

PMID:
21747083
18.

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators.

Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1.

19.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T.

Blood. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13.

20.

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators.

Haematologica. 2011 Feb;96(2):315-8. doi: 10.3324/haematol.2010.031070. Epub 2010 Dec 20.

Supplemental Content

Loading ...
Support Center